Literature DB >> 29159414

Hepatitis B Vaccination, Screening, and Linkage to Care: Best Practice Advice From the American College of Physicians and the Centers for Disease Control and Prevention.

Winston E Abara1, Amir Qaseem1, Sarah Schillie1, Brian J McMahon1, Aaron M Harris1, George M Abraham, Robert Centor, Douglas M DeLong, Heather E Gantzer, Carrie A Horwitch, Linda L Humphrey, Janet A Jokela, Joseph Ming Wah Li, Robert H Lohr, Ana María López, Robert M McLean.   

Abstract

Background: Vaccination, screening, and linkage to care can reduce the burden of chronic hepatitis B virus (HBV) infection. However, recommendations vary among organizations, and their implementation has been suboptimal. The American College of Physicians' High Value Care Task Force and the Centers for Disease Control and Prevention developed this article to present best practice statements for hepatitis B vaccination, screening, and linkage to care.
Methods: A narrative literature review of clinical guidelines, systematic reviews, randomized trials, and intervention studies on hepatitis B vaccination, screening, and linkage to care published between January 2005 and June 2017 was conducted. Best Practice Advice 1: Clinicians should vaccinate against hepatitis B virus (HBV) in all unvaccinated adults (including pregnant women) at risk for infection due to sexual, percutaneous, or mucosal exposure; health care and public safety workers at risk for blood exposure; adults with chronic liver disease, end-stage renal disease (including hemodialysis patients), or HIV infection; travelers to HBV-endemic regions; and adults seeking protection from HBV infection. Best Practice Advice 2: Clinicians should screen (hepatitis B surface antigen, antibody to hepatitis B core antigen, and antibody to hepatitis B surface antigen) for HBV in high-risk persons, including persons born in countries with 2% or higher HBV prevalence, men who have sex with men, persons who inject drugs, HIV-positive persons, household and sexual contacts of HBV-infected persons, persons requiring immunosuppressive therapy, persons with end-stage renal disease (including hemodialysis patients), blood and tissue donors, persons infected with hepatitis C virus, persons with elevated alanine aminotransferase levels (≥19 IU/L for women and ≥30 IU/L for men), incarcerated persons, pregnant women, and infants born to HBV-infected mothers. Best Practice Advice 3: Clinicians should provide or refer all patients identified with HBV (HBsAg-positive) for posttest counseling and hepatitis B-directed care.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29159414     DOI: 10.7326/M17-1106

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  25 in total

Review 1.  Promising practices for the prevention of liver cancer: a review of the literature and cancer plan activities in the National Comprehensive Cancer Control Program.

Authors:  Behnoosh Momin; Alexander J Millman; Danielle Beauchesne Nielsen; Michelle Revels; C Brooke Steele
Journal:  Cancer Causes Control       Date:  2018-12-01       Impact factor: 2.506

2.  Improving Hepatitis B Care in the US: A Case for a New "Ryan White" Program.

Authors:  Jonathan D Alpern; Thomas M Leventhal; Nathan C Bahr
Journal:  J Health Care Poor Underserved       Date:  2020

3.  Hepatitis B vaccine development and implementation.

Authors:  Hong Zhao; Xiaoying Zhou; Yi-Hua Zhou
Journal:  Hum Vaccin Immunother       Date:  2020-03-18       Impact factor: 3.452

Review 4.  Epidemiology and Prevention of Tuberculosis and Chronic Hepatitis B Virus Infection in the United States.

Authors:  Amit S Chitnis; Ramsey Cheung; Robert G Gish; Robert J Wong
Journal:  J Immigr Minor Health       Date:  2021-06-23

5.  Disparities in Hepatitis B Virus Infection and Immunity Among New York City Asian American Patients, 1997 to 2017.

Authors:  Amy S Tang; Janice Lyu; Su Wang; Qingqing He; Perry Pong; Aaron M Harris
Journal:  Am J Public Health       Date:  2018-11       Impact factor: 9.308

Review 6.  Vaccines for immunoprevention of cancer.

Authors:  Tomohiro Enokida; Alvaro Moreira; Nina Bhardwaj
Journal:  J Clin Invest       Date:  2021-05-03       Impact factor: 14.808

7.  Chronic Hepatitis B and HIV Coinfection: A Continuing Challenge in the Era of Antiretroviral Therapy.

Authors:  H Nina Kim
Journal:  Curr Hepatol Rep       Date:  2020-09-16

8.  Hepatitis B prevalence association with sexually transmitted infections: a systematic review and meta-analysis.

Authors:  Elliot Marseille; Aaron M Harris; Hacsi Horvath; Andrea Parriott; Mohsen Malekinejad; Noele P Nelson; Michelle Van Handel; James G Kahn
Journal:  Sex Health       Date:  2021-07       Impact factor: 2.706

9.  A Best Practice Alert for Identifying Hepatitis B-Infected Patients.

Authors:  Malini B DeSilva; Amy Kodet; Patricia F Walker
Journal:  Am J Trop Med Hyg       Date:  2020-05-14       Impact factor: 2.345

10.  Epidemiological trends of HBV and HDV coinfection among Viennese HIV+ patients.

Authors:  Caroline Schmidbauer; David Chromy; Victor U Schmidbauer; Michael Schwarz; Mathias Jachs; David J M Bauer; Teresa Binter; Michael Apata; Dung T Nguyen; Mattias Mandorfer; Benedikt Simbrunner; Armin Rieger; Florian Mayer; Monika Breuer; Robert Strassl; Ralf Schmidt; Heidemarie Holzmann; Michael Trauner; Michael Gschwantler; Thomas Reiberger
Journal:  Liver Int       Date:  2021-08-05       Impact factor: 8.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.